Aequus Ramps Up Supply Amid Glaucoma Drug Shortage
Company Announcements

Aequus Ramps Up Supply Amid Glaucoma Drug Shortage

Aequus Pharmaceuticals (TSE:AQS) has released an update.

Aequus Pharmaceuticals responds to the Canadian shortage of 0.03% bimatoprost, a key glaucoma treatment, by ramping up supply of its preservative-free Zimed® PF eye drops. The company anticipates increased demand and sales revenue for its unique multi-dose product in the wake of this shortage. Aequus is focused on ensuring continuous patient access to this essential medication.

For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Reports Revenue Growth Amid Restructuring
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Reports Strong Q2 Financials
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Celebrates Zimed® PF Sales Record
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App